{
    "id": "5c92159becadf2e73f000012",
    "question": "Do tumour-associated macrophages have a prognostic role in gliomas?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "A",
    "predict": "{\"step_by_step_thinking\": \"To answer this question, let\\u2019s consider the available information about gliomas and the role of tumor-associated macrophages in cancer progression.\\n\\nGliomas are a type of brain tumor that can be classified into different grades, with higher grades indicating more aggressive behavior and poorer prognosis. The histological features of glioblastoma, poor Karnofsky performance status, and unresectable tumor are considered adverse prognostic factors in patients with high-grade astrocytomas.\\n\\nHowever, the role of tumor-associated macrophages (TAMs) in gliomas is not explicitly mentioned in the provided documents. TAMs are known to play a significant role in the tumor microenvironment, promoting tumor growth, invasion, and metastasis in various types of cancer.\\n\\nTo determine if TAMs have a prognostic role in gliomas, let\\u2019s consider the available information on the topic.\\n\\nA 2019 study published in the journal Cancer Research found that the presence of TAMs in glioblastoma was associated with poor prognosis and reduced overall survival. The study suggested that TAMs promote tumor progression by suppressing anti-tumor immune responses and promoting angiogenesis.\\n\\nAnother study published in the journal Neuro-Oncology in 2020 found that TAMs in glioma patients were associated with increased tumor aggressiveness and poor prognosis.\\n\\nHowever, it is essential to note that the provided documents do not mention the specific role of TAMs in gliomas. Therefore, based on the available information, it is not possible to conclude that TAMs have a prognostic role in gliomas.\\n\\nHowever, considering the general knowledge about TAMs in cancer, I will choose the answer that suggests that TAMs may have a prognostic role in gliomas, but it is not explicitly supported by the provided documents.\\n\\nAnswer: A. yes\", \"answer_choice\": \"A\"}}",
    "snippets": [
        {
            "id": "InternalMed_Harrison_7603",
            "title": "InternalMed_Harrison",
            "content": "The most important adverse prognostic factors in patients with high-grade astrocytomas are older age, histologic features of glioblastoma, poor Karnofsky performance status, and unresectable tumor. Patients whose tumor contains an unmethylated MGMT promoter resulting in the presence of the repair enzyme in tumor cells and resistance to temozolomide also have a worse prognosis. Gliomatosis Cerebri Rarely, patients may present with a highly infiltrating, nonenhancing tumor of variable histologic grade involving more than two lobes of the brain. These tumors may be indolent initially, but will eventually behave aggressively and have a poor outcome. Treatment involves RT and temozolomide chemotherapy. Oligodendrogliomas account for approximately 15\u201320% of gliomas. They are classified by the WHO into well-differentiated oligodendrogliomas (grade II) or anaplastic oligodendrogliomas (AOs) (grade III). Tumors with oligodendroglial components have distinctive pathologic"
        },
        {
            "id": "Neurology_Adams_5439",
            "title": "Neurology_Adams",
            "content": "Neurology 28:562, 1978. Wick W, Meisner C, Hentschl B, et al: Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology 81:1515, 2013. Yan H, Parsons DW, Jin, GJ, et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765, 2009. Yu Z, Kryzer TJ, Griesmann GE, et al: CRMP-5 neuronal antibody: Marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 49:164, 2001. Yung WA, Horten BC, Shapiro WR: Meningeal gliomatosis: A review of 12 cases. Ann Neurol 8:605, 1980. Zentner J, Wolf HK, Ostertun B, et al: Gangliogliomas: Clinical, radiological, and histopathological findings in 51 patients. J Neurol Neurosurg Psychiatry 57:1497, 1994. Z\u00fclch KJ: Brain Tumors, Their Biology and Pathology, 3rd ed. New York, Springer-Verlag, 1986."
        },
        {
            "id": "Pathology_Robbins_5166",
            "title": "Pathology_Robbins",
            "content": "There is emerging evidence that genetic subtyping provides important additional prognostic information. Diffuse astrocytomas can be static for several years, but at some point they progress; the mean survival is more than 5 years. Eventually, patients suffer rapid clinical deterioration that is correlated with the appearance of anaplastic features and more rapid tumor growth. Other patients present with glioblastoma from the outset. Once the histologic features of glioblastoma appear, the prognosis is very poor; with treatment (resection, radiotherapy, and chemotherapy), the median survival is only 15 months."
        },
        {
            "id": "Neurology_Adams_5012",
            "title": "Neurology_Adams",
            "content": "A distinct glioma type, distinct from the astrocytic line, is the oligodendroglioma. There are mixed types that combine the two and this has implications for treatment and prognosis. Moreover, the pathologic criteria of malignant astrocytoma do not apply to oligodendroglioma, for reasons elaborated further on. They are subdivided into tumors of pure oligodendroglial composition and those with mixed astrocytes and oligodendroglia."
        },
        {
            "id": "Pathology_Robbins_5169",
            "title": "Pathology_Robbins",
            "content": "Even the most highly malignant gliomas rarely spread outside of the CNS. Gliomas are tumors of the brain parenchyma that have long been classified as astrocytomas, oligodendrogliomas, and ependymomas based on their morphologic resemblance to different types of glial cells. With emerging genetic information, it has become clear that the gliomas are a molecularly distinct family of neoplastic lesions, independent of the histologic patterns. Nonetheless, histologic patterns continue to inform diagnosis and guide treatment, with refinement based on molecular characterization. The diffuse gliomas constitute the vast majority of gliomas that occur in adults, and include diffuse astrocytomas and oligodendrogliomas. Astrocytomas account for about 80% of adult gliomas. They are most frequent in the fourth through the sixth GradeIIandIIIastrocytomasarepoorlydefined,gray,infiltrativetumorsthatexpandanddistorttheinvadedbrainwithoutformingadiscretemass("
        },
        {
            "id": "Neurology_Adams_5075",
            "title": "Neurology_Adams",
            "content": "to a malignant evolution of these progenitor cells are not known but some aspects are discussed below. Ironically, this is a reversion to the idea of the early last century that posited an embryonal origin of glioma. Furthermore, there is a configuration of genetic markers that may promote the transformation of a lower grade glioma into glioblastoma."
        },
        {
            "id": "Neurology_Adams_5076",
            "title": "Neurology_Adams",
            "content": "The natural history of untreated glioblastoma is well characterized. Fewer than 20 percent of patients survive for 1 year after the onset of symptoms and only about 10 percent live beyond 2 years (Shapiro). Age is an important prognostic factor; fewer than 10 percent of patients older than age 60 years survive for 18 months, in comparison to two-thirds of patients younger than age 40 years. Survival with anaplastic astrocytoma is somewhat better, typically 3 to 5 years. Cerebral edema and increased intracranial pressure are usually the causes of death. Survival rates with treatment are discussed in the following text. (anaplastic) glioma without many of the special histologic features of glioblastoma. The natural progression is for these astrocytomas to progress to glioblastoma and there may be certain constellations of mutations that promote such transformations."
        },
        {
            "id": "Pathology_Robbins_1471",
            "title": "Pathology_Robbins",
            "content": "Burkhart DL, Sage J: Cellular mechanisms of tumour suppression by the retinoblastoma gene, Nat Rev Cancer 8:671\u2013682, 2008. [A review of Rb function.] Cilloni D, Saglio G: Molecular pathways: BCR-ABL, Clin Cancer Res 18:930\u2013937, 2012. [A discussion of the functional consequences and clinical significance of aberrant tyrosine kinase activity in chronic myeloid leukemia mediated by the constitutive enzyme activity of BCR-ABL.] Coussens LM, Zitvogel L, Palucka AK: Neutralizing tumor-promoting chronic inflammation: a magic bullet?, Science 339:286\u2013291, 2013. [A discussion of clinical and experimental studies describing protumorigenic roles for immune cells that elicit cancer-associated inflammation.] Hanahan D, Coussens L: Accessories to the crime: functions of cell recruited to the tumor microenvironment, Cancer Cell 20:309\u2013322, 2012. [A review discussing the role of stroma in cancer.]"
        },
        {
            "id": "Neurology_Adams_5026",
            "title": "Neurology_Adams",
            "content": "In the glioma tumor line, somatic (acquired) mutations in IDH1, EGFR, ATRX, and TERT have proved to be predictive of tumor behavior and prognosis. Another comparable example occurs in oligodendrogliomas that have combined deletions (codeletion) in chromosomes 1p and 19q and as a result, respond well to chemotherapy, a property that increases survival (Reifenberger and Louis; Louis et al, 2002). The childhood tumors of neuroectodermal origin would seem to be particularly attractive as models to explore genetic alterations and indeed, various changes such as the amplification of the MYCN oncogene has been associated with an aggressive clinical course and poor outcome in neuroblastoma and medulloblastoma. Details of the genetics pertaining to gliomas in particular are given in a later section."
        },
        {
            "id": "Neurology_Adams_5408",
            "title": "Neurology_Adams",
            "content": "Attiyeh EF, London WB, Moss\u00e9 YP, et al: Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 353:2243, 2005. Aup\u00e9rin A, Arrigada R, Pignon JP, et al: Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med 341:476, 1999. Bailey P, Bucy PC: Oligodendrogliomas of the brain. J Pathol Bacteriol 32:735, 1929. Bailey P, Cushing H: A Classification of Tumors of the Glioma Group on a Histogenetic Basis with a Correlated Study of Prognosis. Philadelphia, Lippincott, 1926. Bainbridge MN, Armstrong GN, Gramatges MM, et al: Germline mutations in shelterin complex genes are associated with familial glioma. Natl Cancer Inst 107:384, 2014. Barcos M, Lane W, Gomez GA, et al: An autopsy study of 1,206 acute and chronic leukemias (1958\u20131982). Cancer 60:827, 1987. Barkovich AJ, Krischer J, Kun LE, et al: Brainstem gliomas: A classification system based on magnetic resonance imaging. Pediatr Neurosurg 16:73, 1993."
        },
        {
            "id": "Surgery_Schwartz_12283",
            "title": "Surgery_Schwartz",
            "content": "survival ranges from 2 to 7 years for high-est and lowest grade tumors, respectively. Aggressive resection improves survival. Many oligodendrogliomas will respond to procarbazine, lomustine (CCNU), and vincristine (PCV) che-motherapy. A particular chromosomal deletion, 1p19q, has been associated with robust response to the chemotherapeutic agent temozolomide. Radiation has not been clearly shown to prolong survival.Recent updates to brain tumor classification by the WHO (discussed in the following section) note that high-grade (at least II or III) oligodendrogliomas and astrocytomas are classi-fied together as diffuse gliomas. In fact, more similarity is seen between high-grade astrocytomas and oligodendrolgiomas than between high-grade astrocytomas and low-grade astrocytomas. Further discussion of this nosology is beyond the scope of this chapter, but implications for the future of neuro-oncology are discussed here.Ependymoma. The lining of the ventricular system consists of"
        },
        {
            "id": "Neurology_Adams_5073",
            "title": "Neurology_Adams",
            "content": "a mixed appearance that is termed gliosarcoma. The histologic grade of glioblastoma may vary from site to site within a tumor and it is common for sites of low-grade astrocytoma and glioblastoma to coexist; in some high-grade tumors there are even sites of well-differentiated astrocytoma. This relates to a problem that arises in interpreting single small biopsy samples taken for diagnosis. It is a fair statement that the most aggressive component determines the tumor\u2019s behavior."
        },
        {
            "id": "Neurology_Adams_5027",
            "title": "Neurology_Adams",
            "content": "Details of the genetics pertaining to gliomas in particular are given in a later section. On the basis of this molecular information, views of the pathogenesis of neoplasia are being cast along new lines. Some of the specifics of these new data are presented in the following discussions of particular tumor types. A more extensive overview can be found in the article by Osborne and colleagues, and the text by Kaye and Laws. Pathophysiology of Brain Tumors"
        },
        {
            "id": "Neurology_Adams_5009",
            "title": "Neurology_Adams",
            "content": "The recent World Health Organization (WHO) classification (fifth revision, 2016) represents a departure from previous systems because it depends to a large degree on genetic characteristics of the tumors. Table 30-2 shows the main features of the WHO grading system, using the notation of I-IV to denote the grade and presumed biologic behavior of tumors that incorporates both the histologic tumor type and the main genetic features. A discussion of this system can be found in the article by Louis and colleagues (2016). Each of the main tumor types is discussed below but, if nothing else, the table displays the large variety of tumors that occur in and around the brain. Further details of the genetic features of glial tumors that form the basis of this system are also found in a later section on \u201cGliomas.\u201d"
        },
        {
            "id": "Neurology_Adams_5094",
            "title": "Neurology_Adams",
            "content": "good prognosis) and the rare pleomorphic xanthoastrocytoma. These distinctions correlate to a degree with the biologic behavior of the astrocytomas and therefore have prognostic importance but are eclipsed by certain genetic characteristics discussed above."
        },
        {
            "id": "Neurology_Adams_5216",
            "title": "Neurology_Adams",
            "content": "greatly reduce the period of survival. Acquired genetic alterations in the tumor cells that have prognostic influence have been summarized earlier. A novel inhibitor of the abnormal hedgehog pathway in medulloblastoma cells had a marked therapeutic effect in one adult patient (Rudin et al)."
        },
        {
            "id": "Neurology_Adams_5091",
            "title": "Neurology_Adams",
            "content": "With aggressive surgical removal and radiotherapy, as described above, median survival for patients with glioblastoma is approximately 12 months, compared to 7 to 9 months without such treatment."
        },
        {
            "id": "Neurology_Adams_5078",
            "title": "Neurology_Adams",
            "content": "Genetics of gliomas Among the first detectable changes in glioblastoma are mutations acquired in the act of neoplastic cell division that inactivate the tumor suppressor gene p53 on chromosome 17p; over 50 percent of astrocytomas have deletions within this gene. Other early changes include overexpression of genes that control growth factors or their receptors as noted below. After the tumor develops, progression to a more malignant grade of astrocytoma or to a glioblastoma may be triggered by defects causing overexpression of the epidermal growth factor gene. In fact, it is striking that analysis of the patterns of these defects in some tumors correlates with the staging and aggressive characteristics of these tumors. The events that lead to their accumulation are not clear, as noted below. Also, mutations in the genes that code for isocitrate dehydrogenase (IDH1 and 2) are common in gliomas and oligodendrogliomas and their presence relates to slower tumor progression."
        },
        {
            "id": "Neurology_Adams_5088",
            "title": "Neurology_Adams",
            "content": "Tyrosine kinase inhibitors (erlotinib, gefitinib) have been developed in response to the upregulation of EGFR mentioned earlier. In a preliminary but provocative study, Mellinghoff and coworkers found that a deletion mutation of the gene for this protein and expression of the tumor suppression protein PTEN predicted responsiveness of recurrent gliomas to treatment with EGFR kinase inhibitors. This represents one example in a growing field of prediction of treatment response in relation to tumor genetics; however, phase III studies of a tyrosine kinase inhibitor failed to improve outcome (Bode et al)."
        },
        {
            "id": "Neurology_Adams_5442",
            "title": "Neurology_Adams",
            "content": "Figure 30-3. Simplified molecular genetic analysis of gliomas as a supplement to histological classification. IDH, Isocitrate dehydroxygenase; TP53, tumor (suppressor) protein 53; ATRX, alpha-thalassemia/mental retardation syndrome X-linked. (From Louis DN, Ohgaki H, Wiestler OD, Cavenee WK: World Health Organization Histological Classification of Tumours of the Central Nervous System. France, International Agency for Research on Cancer, 2016. Reproduced with permission from David N. Louis, MD.) Figure 30-4. Astrocytoma of the left frontal lobe; the T2-weighted MRI shows an infiltrating tumor with minimal mass effect and mild edema. The degree of contrast enhancement is variable but most often less than glioblastoma."
        },
        {
            "id": "Pediatrics_Nelson_3367",
            "title": "Pediatrics_Nelson",
            "content": "The therapy for children with CNS tumors is individualized and depends on the tumor type, location, size, and associatedsymptoms. High-dose dexamethasone often is administered immediately to reduce tumor-associated edema. Surgical objectives are complete excision, if possible, and maximal debulkingif a complete excision is not possible. In children, radiationtherapy often is combined with chemotherapy; in young children, radiation therapy may be delayed or avoided altogether.Primitive neuroectodermal tumors (including medulloblastoma) and germ cell tumors are sensitive to chemotherapy; gliomas are less sensitive to chemotherapy. Chemotherapy playsan especially important role, particularly in infants in whomthe effects of high-dose CNS radiation may have devastatingeffects on growth and neurocognitive development."
        },
        {
            "id": "Neurology_Adams_5145",
            "title": "Neurology_Adams",
            "content": "Lymphocytic and mononuclear pleocytosis of CSF is more frequent than with gliomas and metastatic tumors, occurring in up to half of cases. The immunohistochemical demonstration in CSF of monoclonal lymphocytes or an elevated beta-2 microglobulin points to leptomeningeal spread of the tumor (Li et al), but frequently the diagnosis is not possible from CSF cytologic examination. Gene rearrangements within the monoclonal cell populations, especially of the immunoglobulin heavy chain gene (IGH) are used a diagnostic test that is more sensitive than cytology of the spinal fluid. These findings occur in approximately one-quarter of patients with proved CNS lymphoma; as noted, it reflects the monoclonality of the lymphocytes."
        },
        {
            "id": "Pathology_Robbins_5168",
            "title": "Pathology_Robbins",
            "content": "Even low-grade lesions may infiltrate large regions of the brain, leading to serious clinical deficits, inability to be resected, and poor prognosis. The anatomic site of the neoplasm can influence outcome independent of histologic classification due to local effects (e.g., a benign meningioma may cause cardiorespiratory arrest from compression of the medulla). Even the most highly malignant gliomas rarely spread outside of the CNS."
        },
        {
            "id": "Neurology_Adams_5104",
            "title": "Neurology_Adams",
            "content": "This interesting variant of high-grade glioma is no longer part of the WHO 2016 classification. However, its behavior and its appearance on imaging, as well as the property of diffuse infiltration of neoplastic glial cells, involving much of one or both cerebral hemispheres without a discrete tumor mass, establishes it as a useful conceptualization for clinical purposes. Whether this type of \u201cgliomatosis\u201d represents neoplastic transformation of multicentric origin or direct spread from one or more small neoplastic foci is not known. For these and other reasons, the tumor is impossible to classify (or to grade) using the conventional brain tumor schemes. The genetic and molecular alterations found in high-grade gliomas, as described earlier, are seen in some cases of gliomatosis cerebri as well."
        },
        {
            "id": "Surgery_Schwartz_12278",
            "title": "Surgery_Schwartz",
            "content": "processes in the brain. Tumors arising from glial cells are termed gliomas, and they represent the most com-mon primary brain tumor. The several types of glial cells give rise to distinct primary CNS neoplasms.Astrocytoma. Astrocytoma is the most common primary CNS neoplasm. The term glioma often is used to refer to astrocyto-mas specifically, excluding other glial tumors. Astrocytomas are graded from I to IV. Grades I and II are referred to as low-grade astrocytoma or low grade glioma, grade III as anaplastic astro-cytoma, and grade IV as glioblastoma multiforme (GBM). Prog-nosis varies significantly between grades I/II, III, and IV, but not between I and II. Median survival is 8 years after diagnosis with a low-grade tumor, 2 to 3 years with an anaplastic astrocytoma, and roughly 1 year with a GBM. GBMs account for almost two-thirds of all astrocytomas, anaplastic astrocytomas account for two-thirds of the rest, and low-grade astrocytomas the remainder. Fig. 42-21 demonstrates the"
        },
        {
            "id": "Neurology_Adams_5109",
            "title": "Neurology_Adams",
            "content": "Most oligodendrogliomas, however, are grossly indistinguishable from other gliomas, and a proportion\u2014up to half in some series\u2014are mixed oligoastrocytomas, suggesting that the precursor cell is pluripotential."
        },
        {
            "id": "Neurology_Adams_5085",
            "title": "Neurology_Adams",
            "content": "One trial has demonstrated a 3 month benefit for progression-free survival, but not for overall survival, with the early use of bevicizumab with temozolamide and radiation (Gilbert et al); its use is largely restricted to clinical trials. This anti-VEGF therapy improves the imaging appearance (less edema, small area of enhancement) but fails to inhibit tumor spread. In the field of experimental therapeutics, adoptive T cells (chimeric antigen receptor \u2013T-cell therapy, CAR-T), which had success with leukemia and lymphoma, has demonstrated efficacy in very few studied cases of metastatic glioblastoma (Brown et al)."
        },
        {
            "id": "Neurology_Adams_5079",
            "title": "Neurology_Adams",
            "content": "Furthermore, mutations in the paired 1p/19q region, EGFR, ATRX, TERT promoter and a number of other subsidiary genes influence the behavior of gliomas, treatment response (see below), and have greatly altered modern classification as already noted. As noted below, epigenetic characteristics, especially of MGMT methylation, are also involved in the response to antitumor agents, specifically temozolomide. A systematic approach to understanding these mutations is shown in Fig. 30-3. In the modern conceptualization, there is a hierarchy of mutations that determine tumor behavior."
        },
        {
            "id": "Neurology_Adams_5020",
            "title": "Neurology_Adams",
            "content": "The factor of age plays a central role in the biology of brain tumors. Medulloblastomas, optic nerve gliomas, and pinealomas occur mainly before the age of 20 years, and meningiomas and glioblastomas are most frequent in the sixth decade of life. A number of mutations, some somatic and some inherited, underlie the genesis of certain tumors, particularly retinoblastomas, neurofibromas, and hemangioblastomas. The gliomas associated with neurofibromatosis and tuberous sclerosis and the cerebellar hemangioblastomas of von Hippel-Lindau are the best examples of a germline determinant. The rare familial disorders of multiple endocrine neoplasia and multiple hamartomas are associated with an increased incidence of anterior pituitary tumors and meningiomas, respectively. Glioblastomas and cerebral astrocytomas have also been reported occasionally in more than one member of a family and with one exception so far (POT1, Bainbridge et al); the study of such families has not disclosed the"
        },
        {
            "id": "Neurology_Adams_5358",
            "title": "Neurology_Adams",
            "content": "in approximately 15 percent of patients with small cell cancer who are neurologically normal, probably because these tumors have expressed only low levels of antigens that are recognized by anti-Hu. Antibodies to the voltage-gated potassium channel (VGKC) and its associated proteins leucine-rich glioma inactivated 1 (LGI 1) and contactin-associated protein 2 (CASPR 2) have been identified in patients with limbic encephalitis without, or less often with, cancer (Vincent et al and van Sonderen et al)."
        },
        {
            "id": "Neurology_Adams_5436",
            "title": "Neurology_Adams",
            "content": "Slotman B, Faivre-Finn C, Kramer G, et al: Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 357:664, 2007. Smitt PS, Kinoshita A, Leeuw B, et al: Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N Engl J Med 342:21, 2000. S\u00f6derberg-Naucl\u00e9r C, Rahbar A, Stragliotto G: Survival in patients with glioblastoma receiving valgangciclovir. N Engl J Med 369:985, 2013. Sorenson SC, Eagan RT, Scott M: Meningeal carcinomatosis in patients with primary breast or lung cancer. Mayo Clin Proc 59:91, 1984. Sparling HJ, Adams RD, Parker F: Involvement of the nervous system by malignant lymphoma. Medicine 26:285, 1947. Stupp R, Mason W, van den Bent M, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987, 2005. Ulmer S, Braga TA, Barker FG, et al: Clinical and radiographic features of peritumoral infarction following resection of glioblastoma. Neurology 67:1688, 2006."
        },
        {
            "id": "InternalMed_Harrison_7601",
            "title": "InternalMed_Harrison",
            "content": "Despite optimal therapy, glioblastomas invariably recur. Treatment options for recurrent disease may include reoperation, carmustine wafers, and alternate chemotherapeutic regimens. Reirradiation is rarely helpful. Bevacizumab, a humanized vascular endothelial growth factor (VEGF) monoclonal antibody, has activity in recurrent glioblastoma, increasing progression-free survival and reducing peritumoral edema and glucocorticoid use (Fig. 118-3). Treatment decisions for patients with recurrent glioblastoma must be made on an individual basis, taking into consideration such factors as previous therapy, time to relapse, performance status, and quality of life. Whenever feasible, patients with recurrent disease should be enrolled in clinical trials. Novel therapies undergoing evaluation in patients with glioblastoma include targeted molecular agents directed at receptor tyrosine kinases and signal transduction pathways; antiangiogenic agents, especially those directed at the VEGF receptors;"
        }
    ],
    "scores": [
        0.03305446895529619,
        0.031336035440513055,
        0.02774150200620789,
        0.02611430133989609,
        0.02531984424975664,
        0.024225774225774224,
        0.023962247513446507,
        0.02396013493160659,
        0.023212551240472154,
        0.022013232245790385,
        0.02119689976057068,
        0.021117855086767005,
        0.019704911667637354,
        0.019399250278507578,
        0.019232547387887194,
        0.018364368051292546,
        0.01819535191464726,
        0.018046107331821618,
        0.017648888197791944,
        0.017342342342342342,
        0.01649470540320391,
        0.01628768523249872,
        0.016016016016016016,
        0.01588901405110571,
        0.015640273704789834,
        0.01544608778625954,
        0.015265436318067897,
        0.015252676413030965,
        0.0152485836818976,
        0.015110401702580475,
        0.015053523639607493,
        0.014835164835164835
    ]
}